Survodutide

Description

Survodutide

The product is only intended for laboratory research use and not for human consumption. 

Available quantities:

• 10 mg

Product information

Product	Survodutide
Peptide purity (HPLC)	98-99%
CAS	2805997-46-8
Molar mass	4232 g/mol
Chemical formula	C192H289N47O61
Synonyms	2805997-46-8, GTPL13383, EX-A7878, BI456906
Source	Synthetic
Form	Powder
Shelf Life	12–14 months under recommended conditions

 

Molecular Sequence of Survodutide

• His–Ser–Gln–Gly–Thr–Phe–Thr–Ser–Asp–Tyr–Ser–Lys–Tyr–Leu–Asp–Ser–Arg–Arg–Ala–Gln–Asp–Phe–Val–Gln–Trp–Leu–Met–Asn–Thr–NH₂
  

• Modified glucagon-based peptide
• Dual GLP-1 and glucagon receptor activity
• C-terminal amidation (-NH₂) for enhanced stability
• Fatty-acid side-chain modification for albumin binding
• Designed for prolonged half-life and sustained activity

Handling and Storage of Survodutide

The peptide compound should be stored in a cool and dry place to maximize its stability. For Survodutide lyophilized peptides, it is recommended to store them in the refrigerator between 2°C and 8°C (36°F–46°F) in an airtight container. 

Lab user exposure: 

• Avoid prolonged or repeated exposure.
• Avoid inhalation.
• Avoid contact with eyes or skin.
• Handle inside standard laboratory containment.
• Use gloves, a lab coat, and protective eyewear.

Redissolving:

• Can be reconstituted in sterile distilled water or suitable buffer solutions.
• A small amount of DMSO or 0.1% TFA may be used to test or improve solubility.
• Mix gently, avoid high-temperature heating. 

Choice of container and precautions:

• Low-binding sterile polypropylene to prevent adsorption
• Borosilicate glass vials to prevent adsorption in the glass walls
• Avoid polystyrene
• Avoid lab plastic containers

Overview of Survodutide 

Survodutide is a synthetic peptide developed as a dual agonist of the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. It is designed to combine the complementary metabolic actions of both pathways, aiming to influence appetite regulation, energy expenditure, and overall metabolic balance in controlled research settings.
Survodutide targets both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR) and is developed by Boehringer Ingelheim. It is also being researched for obesity and metabolic disorders in different research models.

Working Mechanism of the Survodutide 

GLP-1 Receptor Activation

Preclinical findings suggest that Survodutide binds to GLP-1 receptors expressed in pancreatic, gastrointestinal, and central nervous system tissues. Activation of these receptors has been associated with:

• Modulation of appetite-regulating neural circuits.
• Slowing of gastric emptying in experimental models.
• Enhanced glucose-dependent insulin signaling under controlled conditions. This pathway is primarily studied for its role in appetite control and metabolic regulation.

Glucagon Receptor Activation

Survodutide also interacts with glucagon receptors, particularly in hepatic tissues. Experimental data indicate that glucagon receptor activation may:

• Stimulate hepatic energy utilization
• Promote lipid mobilization and fatty-acid oxidation
• Increase basal energy expenditure in laboratory models

Balanced Dual-Receptor Signaling

A key feature of Survodutide is its engineered balance between GLP-1 and glucagon receptor activation. Structural modifications are designed to mitigate excessive hyperglycemic effects of glucagon signaling while preserving its metabolic benefits. This balanced co-activation enables coordinated control of energy intake and energy expenditure in research settings.

Prolonged Activity and Stability

Preclinical studies indicate that Survodutide includes molecular modifications such as C-terminal amidation and fatty-acid side-chain attachment, which facilitate albumin binding. These features contribute to:

• Extended circulation time
• Reduced enzymatic degradation
• Sustained receptor engagement in experimental models

TFA Salt Form 

Survodutide is provided in their TFA salt form. Residual trifluoroacetate content is typically up to 10% w/w. It depends on the final formulation and lyophilization conditions. The exact TFA content can be confirmed by batch-specific COA.

Disclaimer

Survodutide peptides are intended exclusively for laboratory research purposes. RCDbio products are not intended to diagnose, treat, cure, or prevent any disease. The Food and Drug Administration has not evaluated the statements on our website. By purchasing, you agree to our Terms and Conditions.